Innovative Treatment Flyte offers an FDA-cleared, in-home treatment for female urinary incontinence that delivers surgical-level outcomes, presenting a compelling alternative to traditional in-clinic procedures and expanding options for women seeking conservative care.

Strong Market Traction With recent funding rounds totaling over $10 million and a growing revenue range of 1M to 10M, the company demonstrates strong investor confidence and increasing market adoption, creating opportunities to target healthcare providers and pelvic health clinics.

Upcoming Product Launch The launch of the next-generation Flyte System enhances treatment tracking and outcome optimization, providing an opportunity to engage healthcare professionals and clinics seeking innovative solutions that improve patient engagement and results.

Expansion & Leadership Recent strategic hires and high-profile appointments, including a new board member, suggest expansion plans and increased credibility, presenting opportunities to partner or align with new leadership initiatives to accelerate market penetration.

Focus on Women's Health As a dedicated women's health company addressing pelvic floor disorders, Flyte is well-positioned to collaborate with clinics, hospitals, and health systems aiming to expand conservative treatment options and improve patient outcomes in pelvic health.